Kidney Precision Medicine Project Central Hub (U24 Clinical Trial Not Allowed)

The Kidney Precision Medicine Project Central Hub opportunity is issued by the National Institutes of Health within the U.S. Department of Health and Human Services, specifically under the National Institute of Diabetes and Digestive and Kidney Diseases. This initiative is part of a broader federal effort to advance precision medicine approaches for kidney disease, including both acute kidney injury and chronic kidney disease. The program reflects a coordinated, multi-site research infrastructure designed to generate high-resolution molecular and clinical data that can improve disease classification, identify therapeutic targets, and ultimately enhance patient outcomes. The purpose of this funding opportunity is to establish and support a Central Hub that will serve as the operational and scientific backbone of the Kidney Precision Medicine Project. The Central Hub will be responsible for coordinating activities across multiple collaborating entities, including Recruitment Sites, Tissue Interrogation Sites, and the Kidney Tissue Atlas Coordinating Center. Core responsibilities include collecting, managing, and de-identifying clinical data and biological samples, ensuring data quality, and facilitating integration across research components. The Central Hub is also expected to provide infrastructure support, scientific leadership, administrative coordination, and project management oversight. Funding under this opportunity is provided through a cooperative agreement mechanism, indicating substantial involvement from the funding agency during the project period. The estimated total program funding is five million dollars, with one anticipated award. While specific award ceiling and floor amounts are not defined, the funding is intended to support comprehensive operational capabilities, including data systems, quality control frameworks, and collaborative scientific activities. There is no cost sharing or matching requirement associated with this program. Eligibility for this opportunity is broad and inclusive, encompassing a wide range of domestic and international entities. Eligible applicants include institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit entities, small businesses, state and local governments, tribal governments and organizations, public housing authorities, and independent school districts. Additional eligible applicants include federal agencies, U.S. territories, regional organizations, and foreign institutions. This inclusivity reflects the interdisciplinary and collaborative nature of the project, which requires expertise from diverse organizational types. The application process is expected to follow standard NIH submission procedures through Grants.gov, although specific submission components are not detailed in the forecast notice. Applicants should anticipate preparing comprehensive proposals that address scientific approach, data management plans, infrastructure capabilities, and collaborative strategies. Evaluation criteria will likely emphasize scientific merit, feasibility, organizational capacity, and the ability to coordinate across multiple project components. The timeline for this opportunity indicates that it is currently in a forecast stage. The estimated posting date is July 5, 2026, with an application due date of October 5, 2026. Awards are expected to be made by June 1, 2027, with a project start date of July 1, 2027. As a forecasted opportunity, applicants are encouraged to begin early planning and engagement to prepare for the formal release. No recurring cycle is indicated, suggesting this may be a one-time or irregular funding opportunity. For additional information, applicants may contact the listed program official at the National Institutes of Health. This opportunity represents a significant investment in advancing kidney disease research through coordinated, data-driven approaches and offers a unique chance for organizations to contribute to a national precision medicine initiative.